Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

Understanding and Overcoming High Clearance and Poor Bioavailability: Fundamentals, Investigations and Strategies for Drug Discovery


Speakers: Matthew Wright (Genentech), Vahid Zia (Gilead), Simon Wong (Genentech), Eugene Chen (Genentech), Jaochim Rudolph (Genentech), John Link (Gilead), Fabio Broccatelli (Genentech), Bernard Murray (Gilead)
Organizers: Matthew Wright (Genentech)
Date: 2018-05-22
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Catalent Pharma Solutions; Worldwide Clinical Trials
Vendor show vendors registered to date: (18)Absorption Systems; ACROBiosystems; BioDuro; Celerion; Celerion; ChemPartner; Cyprotex; Cytovier; Foster Delivery Science; Intertek; Pacific BioLabs; Pion Inc.; QPS; Quotient Sciences; Sekisui XenoTech, LLC; Selvita Inc.; Seventh Wave; Simulations Plus, Inc.
Registration: http://www.PBSS.org
Registration deadline:2018-05-21  (it will close sooner if the seating cap is reached)

About the Topic

Poor exposure following oral administration is a common challenge facing discovery programs and consequently a frequent focus for DMPK scientists. Frequently, potent compounds cannot be further developed due to less-than-ideal ADME (absorption, distribution, metabolism, and excretion) properties that prevent the compounds to be available following oral administration. Beyond the discovery phase the importance of understanding and optimizing oral exposure continues in the preclinical and ultimately clinical phases of drug development. Inadequate oral exposure could be due to suboptimal physicochemical properties, or problems in absorption from the gut, or first-pass metabolism in the gut and liver, or high intrinsic clearance of the compounds.

The focus of this workshop/symposium is on: 1) to identify and learn about the issues that contribute to low oral exposure, 2) to discuss approaches that one could use to overcome those challenges, 3) to present additional methodologies that can aid in solving exposure problems and 4) to provide suggestions on how to work with partners in Medicinal Chemistry and Biological Sciences within Project Teams.

This workshop/symposium will cover the following topics:

  • Pharmacokinetic concepts – absorption, bioavailability, and clearance factors contributing to low oral exposure
  • Physiological factors that affect oral exposure
  • Physicochemical factors that influence oral exposure
  • Metabolism-based issues that give rise to poor oral exposure
  • Transporter-based issues that give rise to poor oral exposure
  • How to identify the source of problem in oral exposure – properties of the molecules or conditions of the experiment?
  • Biopharmaceutical Aspects of oral drug exposure
  • Approaches to overcome oral exposure issues, including case studies
  • Enabling Exposure of ADME Challenged compounds
  • What do Medicinal Chemists/Biologists want and how can we work with them

Workshop Agenda:

8:45 - 8:50am  PBSS Welcome M. Wright

8:50 - 9:25am  1. Pharmacokinetic Concepts (Matthew Wright)

9:25 – 10:00 am  2. Absorption of Drugs from the GI Tract (Vahid Zia)

10:00 - 10:20am  Major Sponsor Presentation Worldwide Clinical Trials

10:20 - 10:35am  Break

10:35 - 11:20pm  3. Metabolism-based issues in oral bioavailability (Simon Wong)

11:20 – 12:00 pm  4. Transporter-based issues in oral bioavailability (Eugene Chen)

12:00 - 1:00pm  Lunch

Minisymposium Agenda:

1:00 – 1:45 pm 1. Enabling Technologies to achieve oral exposure (Jaochim Rudolph)

1:45 – 2:30 pm  2. Working in non-Lipinski Space - Discovery of GS-5885 (Ledipasvir) (John Link)

2:30 - 2:45pm  Major Sponsor Presentation Vendor name TBD

2:45 - 3:00pm  Break

3:00 - 3:45pm  3. In silico applications (Fabio Broccatelli)

3:45 – 4:00 pm Break

4:00 - 4:45pm  4. Characterization and differentiation of apparently metabolically stable compounds (Bernard Murray)

4:45 - 5:00pm  Wrap-up (Matthew Wright)


2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 4/24/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Submit a Text Ad